DE69841982D1 - Zusammensetzungen zum einsatz in einer gentherapie zur behandlung von hämophilie - Google Patents

Zusammensetzungen zum einsatz in einer gentherapie zur behandlung von hämophilie

Info

Publication number
DE69841982D1
DE69841982D1 DE69841982T DE69841982T DE69841982D1 DE 69841982 D1 DE69841982 D1 DE 69841982D1 DE 69841982 T DE69841982 T DE 69841982T DE 69841982 T DE69841982 T DE 69841982T DE 69841982 D1 DE69841982 D1 DE 69841982D1
Authority
DE
Germany
Prior art keywords
compositions
hemophilia
treatment
gene therapy
associated virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69841982T
Other languages
English (en)
Inventor
Katherine A High
Roland W Herzog
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Childrens Hospital of Philadelphia CHOP
Original Assignee
Childrens Hospital of Philadelphia CHOP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hospital of Philadelphia CHOP filed Critical Childrens Hospital of Philadelphia CHOP
Application granted granted Critical
Publication of DE69841982D1 publication Critical patent/DE69841982D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69841982T 1997-03-14 1998-03-12 Zusammensetzungen zum einsatz in einer gentherapie zur behandlung von hämophilie Expired - Lifetime DE69841982D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4071197P 1997-03-14 1997-03-14
PCT/US1998/004790 WO1998041240A1 (en) 1997-03-14 1998-03-12 Methods and compositions for use in gene therapy for treatment of hemophilia

Publications (1)

Publication Number Publication Date
DE69841982D1 true DE69841982D1 (de) 2010-12-16

Family

ID=21912503

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69841982T Expired - Lifetime DE69841982D1 (de) 1997-03-14 1998-03-12 Zusammensetzungen zum einsatz in einer gentherapie zur behandlung von hämophilie

Country Status (9)

Country Link
US (3) US6093392A (de)
EP (1) EP1005376B1 (de)
JP (1) JP4289687B2 (de)
AT (1) ATE486614T1 (de)
AU (1) AU745386B2 (de)
CA (1) CA2283639A1 (de)
DE (1) DE69841982D1 (de)
ES (1) ES2355588T3 (de)
WO (1) WO1998041240A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6531455B1 (en) * 1995-03-24 2003-03-11 The Regents Of The University Of California Delivery of polynucleotides by secretory gland expression
US5885971A (en) * 1995-03-24 1999-03-23 The Regents Of The University Of California Gene therapy by secretory gland expression
US20020037867A1 (en) * 1999-02-26 2002-03-28 James M. Wilson Method for recombinant adeno-associated virus-directed gene therapy
US20030215422A1 (en) 1996-09-11 2003-11-20 John A. Chiorini Aav4 vector and uses thereof
US6797505B2 (en) * 1998-05-27 2004-09-28 Cell Genesys, Inc. Recombinant AAV vectors for gene therapy of hemophilia A
US6984517B1 (en) 1998-05-28 2006-01-10 The United States Of America As Represented By The Department Of Health And Human Services AAV5 vector and uses thereof
WO1999061601A2 (en) * 1998-05-28 1999-12-02 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Aav5 vector and uses thereof
US6759237B1 (en) * 1998-11-05 2004-07-06 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
AU780231B2 (en) 1998-11-10 2005-03-10 University Of North Carolina At Chapel Hill, The Virus vectors and methods of making and administering the same
ATE374251T1 (de) * 1999-02-19 2007-10-15 Engene Inc Zusammensetzungen zur gentherapie von diabetes
AU5470900A (en) 1999-06-08 2000-12-28 Children's Hospital Of Philadelphia, The Methods for preventing formation of inhibitory antibodies in the setting of genetherapy
US6610906B1 (en) * 1999-06-09 2003-08-26 The Regents Of The University Of Michigan Nucleotide sequences for gene regulation and methods of use thereof
US7217699B2 (en) * 2000-01-03 2007-05-15 Panagenic International, Inc. Compositions comprising genome segments and methods of using the same
US6855314B1 (en) 2000-03-22 2005-02-15 The United States Of America As Represented By The Department Of Health And Human Services AAV5 vector for transducing brain cells and lung cells
ATE438414T1 (de) * 2000-06-01 2009-08-15 Univ North Carolina Verfahren und zusammensetzungen zur kontrollierter abgabe von rekombinant parvovirus vektoren
AU2001268373A1 (en) * 2000-06-13 2001-12-24 The Children's Hospital Of Philadelphia Methods for administering recombinant adeno-associated virus virions to humans previously exposed to adeno-associated virus
AU2002226028A1 (en) * 2000-11-14 2002-05-27 Board Of Regents, Unversity Of Texas Systems Mutant human factor ix with an increased resistance to inhibition by heparin
US6794376B2 (en) * 2000-12-06 2004-09-21 William Beaumont Hospital Methods and compositions for enhancing diffusion of therapeutic agents through tissue
US20020159978A1 (en) * 2001-02-06 2002-10-31 James Allen Muscle-directed gene transfer by use of recombinant AAV-1 and AAV-6 virions
US7220718B2 (en) 2001-08-03 2007-05-22 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Oral treatment of hemophilia
WO2003018611A2 (en) 2001-08-24 2003-03-06 University Of Victoria Innovation And Development Corporation Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer
US20030198620A1 (en) * 2002-04-16 2003-10-23 Keiya Ozawa Method of treating amino acid metabolic disorders using recombinant adeno-associated virus virions
US7419817B2 (en) 2002-05-17 2008-09-02 The United States Of America As Represented By The Secretary Department Of Health And Human Services, Nih. Scalable purification of AAV2, AAV4 or AAV5 using ion-exchange chromatography
US20040092008A1 (en) * 2002-11-12 2004-05-13 Snyder Richard O. Recombinant AAV vectors for gene therapy of hemophilia A
US8927269B2 (en) 2003-05-19 2015-01-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Avian adenoassociated virus and uses thereof
ES2629380T3 (es) 2003-06-19 2017-08-09 Genzyme Corporation Viriones de AAV con inmunorreactividad reducida y usos de los mismos
WO2005056807A2 (en) 2003-12-04 2005-06-23 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health Bovine adeno-associated viral (baav) vector and uses thereof
US20060078542A1 (en) * 2004-02-10 2006-04-13 Mah Cathryn S Gel-based delivery of recombinant adeno-associated virus vectors
US7722596B2 (en) * 2004-02-26 2010-05-25 Osprey Medical, Inc. Regional cardiac tissue treatment
ATE549037T1 (de) 2004-09-22 2012-03-15 St Jude Childrens Res Hospital Verbesserte expression von faktor-ix in gentherapie-vektoren
CN101124328A (zh) 2004-12-15 2008-02-13 北卡罗来纳查佩尔山大学 嵌合载体
WO2006089340A2 (en) * 2005-02-23 2006-08-31 V-Kardia Pty Ltd Polynucleotide delivery to cardiac tissue
WO2006119432A2 (en) 2005-04-29 2006-11-09 The Government Of The U.S.A., As Rep. By The Sec., Dept. Of Health & Human Services Isolation, cloning and characterization of new adeno-associated virus (aav) serotypes
US8152786B2 (en) * 2006-11-07 2012-04-10 Osprey Medical, Inc. Collection catheter and kit
US9050400B2 (en) * 2008-08-12 2015-06-09 Osprey Medical, Inc. Remote sensing catheter system and methods
US20100041984A1 (en) * 2008-08-12 2010-02-18 James Edward Shapland Impedance sensing device and catheter system
US8889641B2 (en) 2009-02-11 2014-11-18 The University Of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
FR2952374B1 (fr) * 2009-11-06 2012-11-16 Univ Claude Bernard Lyon Production de facteur ix recombinant dans une lignee cellulaire hepatocytaire humaine
WO2011057243A2 (en) * 2009-11-09 2011-05-12 University Of Central Florida Research Foundation, Inc. Administration of plant expressed oral tolerance agents
WO2011071988A1 (en) * 2009-12-08 2011-06-16 Health Research, Inc. Methods and compositions using peroxiredoxin 1 (prx1) as an adjuvant
US9295816B2 (en) * 2009-12-09 2016-03-29 Osprey Medical, Inc. Catheter with distal and proximal ports
ES2680915T3 (es) 2010-01-28 2018-09-11 The Children's Hospital Of Philadelphia Plataforma de fabricación escalable para la purificación de vectores virales y vectores virales purificados de este modo para su utilización en terapia génica
US9175280B2 (en) * 2010-10-12 2015-11-03 Sangamo Biosciences, Inc. Methods and compositions for treating hemophilia B
EP4043025A1 (de) 2011-06-08 2022-08-17 Translate Bio, Inc. Lipidnanoteilchenzusammensetzungen und verfahren zur mrna-freisetzung
EP2721151B1 (de) 2011-06-20 2017-12-06 Mount Sinai School Of Medicine Anti-tnf-therapie für mucopolysaccharidosen und andere lysosomale störungen
US9211372B2 (en) 2011-08-11 2015-12-15 Osprey Medical, Inc. Systems and methods for limb treatment
RU2705249C2 (ru) * 2013-07-12 2019-11-06 Дзе Чилдрен'З Хоспитал Оф Филадельфия Вектор aav и анализ на нейтрализующие антитела против aav (аденоассоциированного вируса)
KR102417915B1 (ko) 2014-03-21 2022-07-07 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 뉴클레아제 없는 게놈 편집
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
EP4215605A1 (de) * 2015-12-11 2023-07-26 The Trustees of The University of Pennsylvania Skalierbares reinigungsverfahren für aav8
EA201892347A1 (ru) 2016-04-15 2019-04-30 Баксалта Инкорпорейтед Способ и устройство для предоставления фармакокинетической схемы дозирования лекарственных препаратов
US10896749B2 (en) 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool
US10842853B2 (en) 2017-05-22 2020-11-24 Baxalta Incorporated Viral vectors encoding recombinant fix with increased expression for gene therapy of hemophilia B
WO2019083171A2 (ko) 2017-10-26 2019-05-02 주식회사 큐로진생명과학 솔루블 vegfr-1 변이체 cdna를 함유하는 raav를 포함하는 황반변성 치료용 조성물
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0107278B1 (de) * 1982-08-04 1989-11-15 National Research Development Corporation Molekulare Klonierung des Gens für menschlichen antihaemophilischen Faktor IX
US5139941A (en) * 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5834266A (en) 1993-02-12 1998-11-10 President & Fellows Of Harvard College Regulated apoptosis
US6342390B1 (en) 1994-11-23 2002-01-29 The United States Of America As Represented By The Secretary Of Health And Human Services Lipid vesicles containing adeno-associated virus rep protein for transgene integration and gene therapy
US5843742A (en) * 1994-12-16 1998-12-01 Avigen Incorporated Adeno-associated derived vector systems for gene delivery and integration into target cells
US5834306A (en) 1994-12-23 1998-11-10 Sri International Tissue specific hypoxia regulated therapeutic constructs
US5858351A (en) * 1996-01-18 1999-01-12 Avigen, Inc. Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
US5846528A (en) * 1996-01-18 1998-12-08 Avigen, Inc. Treating anemia using recombinant adeno-associated virus virions comprising an EPO DNA sequence
US5817784A (en) 1996-08-09 1998-10-06 Amgen Inc. Neurogene
US5866552A (en) * 1996-09-06 1999-02-02 The Trustees Of The University Of Pennsylvania Method for expressing a gene in the absence of an immune response
KR20000068501A (ko) * 1996-09-06 2000-11-25 트러스티스 오브 더 유니버시티 오브 펜실바니아 재조합 아데노-관련 바이러스 지정 유전자 요법을 위한 방법
AU743335B2 (en) * 1996-09-25 2002-01-24 Cell Genesys, Inc. Non-invasive administration of adeno-associated viral vectors

Also Published As

Publication number Publication date
JP2001517221A (ja) 2001-10-02
WO1998041240A1 (en) 1998-09-24
US20110263690A1 (en) 2011-10-27
AU745386B2 (en) 2002-03-21
EP1005376A4 (de) 2004-11-24
US7998734B2 (en) 2011-08-16
ATE486614T1 (de) 2010-11-15
ES2355588T3 (es) 2011-03-29
US20080213222A1 (en) 2008-09-04
JP4289687B2 (ja) 2009-07-01
EP1005376B1 (de) 2010-11-03
EP1005376A1 (de) 2000-06-07
AU6458698A (en) 1998-10-12
US6093392A (en) 2000-07-25
CA2283639A1 (en) 1998-09-24

Similar Documents

Publication Publication Date Title
ATE486614T1 (de) Zusammensetzungen zum einsatz in einer gentherapie zur behandlung von hämophilie
EP0710288A4 (de) Adenovirale vektoren für die behandlung der hämophilie
ATE231549T1 (de) Verfahren zur konservierung von infektiösen rekombinierenden viren, virale wässrige suspension und ihre medizinische verwendung
DE60039766D1 (de) Terologen nukleotidsequenz von einem rekombinanten viralen vektor durch ausgestaltung der sequenz in einer art und weise, dass basenpaarungen innerhalb der sequenz entstehen
DE60140794D1 (de) Von casein abgeleitete peptide und deren anwendung für die therapie
PT836648E (pt) Virus mva recombinante e sua utilizacao
ATE312176T1 (de) Herstellung von rekombinanten muteine des blutgerinnungsfaktors viii in humanen zellinien
WO1995026411A3 (en) Composition and methods for creating syngeneic recombinant virus-producing cells
DE69635349D1 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
DE3789525D1 (de) Das F-Protein vom AIDS-Virus enthaltender Impfstoff.
AU698242B2 (en) Pharmaceutical compositions and utilization thereof particularly for the treatment of neurodegenerative diseases
FR2720756B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
FR2717496B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
WO2002083896A3 (en) Recombinant segmented negative strand virus with a duplicated 3' noncoding flanking sequence, and therapeutic compositions containing the same
EP1916258A3 (de) Erweiterte Expression einer einstämmigen, heterologen Nukleotidsequenz von rekombinanten viralen Vektoren durch Modellierung der Sequenz mit stammübergreifenden Basispaaren
FR2717497B1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
MY134484A (en) Recombinant mva virus, and the use thereof
MY119381A (en) Recombinant mva virus, and the use thereof